{"filing":{"accession_number":"0001193125-26-308409","cik":"0001650648","ticker":"FDMT","company_name":"4D Molecular Therapeutics, Inc.","form":"8-K","filing_date":"2026-07-20","report_date":null,"primary_document":"d98747d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1650648/000119312526308409/d98747d8k.htm"},"events":[{"id":18698,"run_id":16816,"accession_number":"0001193125-26-308409","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"The disclosure reports positive 2-year efficacy and safety data from the PRISM Phase 2b clinical trial of 4D-150 for wet AMD, including consistent BCVA maintenance, CST control, and significant treatment burden reduction (78–87% fewer injections). This represents a material clinical milestone for a biopharmaceutical company advancing toward Phase 3 trials, affecting investor assessment of the therapeutic candidate's viability and commercial potential. While not a specific named event type, this is clearly an operational/clinical development milestone that would influence a reasonable investor's view of the company's pipeline progress.","company_name":"4D Molecular Therapeutics, Inc.","ticker":"FDMT","filing_date":"2026-07-20","form":"8-K","submitted_at":null,"items":[{"id":17584,"accession_number":"0001193125-26-308409","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"The disclosure reports positive 2-year efficacy and safety data from the PRISM Phase 2b clinical trial of 4D-150 for wet AMD, including consistent BCVA maintenance, CST control, and significant treatment burden reduction (78–87% fewer injections). This represents a material clinical milestone for a biopharmaceutical company advancing toward Phase 3 trials, affecting investor assessment of the therapeutic candidate's viability and commercial potential. While not a specific named event type, this is clearly an operational/clinical development milestone that would influence a reasonable investor's view of the company's pipeline progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-20T13:16:45.607086+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":17584,"accession_number":"0001193125-26-308409","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"The disclosure reports positive 2-year efficacy and safety data from the PRISM Phase 2b clinical trial of 4D-150 for wet AMD, including consistent BCVA maintenance, CST control, and significant treatment burden reduction (78–87% fewer injections). This represents a material clinical milestone for a biopharmaceutical company advancing toward Phase 3 trials, affecting investor assessment of the therapeutic candidate's viability and commercial potential. While not a specific named event type, this is clearly an operational/clinical development milestone that would influence a reasonable investor's view of the company's pipeline progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-20T13:16:45.607086+00:00","company_name":"4D Molecular Therapeutics, Inc.","ticker":"FDMT","filing_date":"2026-07-20"}]}